glp-1 contraindications thyroid 470 Nodules and Thyroid Cancer for Primary Care Is it safe for a In a patient who has

In the 1970s, Harvard University researcher Joel Habener, with support from the National Institutes of Health, set out to study the hormone glucagon and its role in blood sugar regulation

Data from preclinical models in mice and human data also suggest that the tolerability and efficacy of GLP-1 agonists vary with the hormonal cycle and that higher circulating estrogen levels are associated with a heightened risk of nausea and vomiting

For people who stopped taking GLP-1 weight-loss medications, patients regained about 60% of the weight they lost within a year, according to the reviews analysis

Risk appears behavioural rather than pharmacological